Objetivo Acute myeloid leukemia (AML) is one of the most deadly cancers. Currently, we do not fully understand how and why AML starts or why it tends to relapse after treatment. Recent discoveries by the applicant and others have identified preleukemic stem and progenitor cells (preL-HSPCs) as the root of AML evolution. Many healthy elderly individuals carry the preleukemic mutations in their preL-HSPCs and yet, do not develop AML. It is also becoming clearer that leukemia evolution is spanning over many years but most research is focused on the late stages of the disease. Population genetics tools are specifically suited for the study of historical evolution however such tools are not well developed in the field of somatic evolution. This proposal will integrate population genetics, stem cell and leukemia biology in order to unravel human leukemia evolution from the very early preleukemic phase to relapse. Novel single cell population genetics tools will be used to describe the naive clonal structure of the human hematopoietic system in both health and disease. A unique cohort of half a million Europeans, who have been followed for years, will be used to understand why only a small fraction of the individuals carrying preleukemic mutations develop AML. Novel genetic analysis will be developed to study the clonal structure of blood cells, years before AML was diagnosed. A large cohort (N=100) of AML patients were collected serially over a year and will be collected until relapse. Detailed molecular and population genetics of this cohort will aid in understanding the mechanism of AML relapse and in developing novel molecular methodologies, that will allow early relapse diagnosis. AML like many other malignancies is diagnosed late in its evolutionary path. In this proposal the evolution of AML before diagnosis and before it relapses will be studied by novel population genetic tools so that the vision of early diagnosis and treatment will become reality. Ámbito científico medical and health sciencesclinical medicineallergologydrug allergymedical and health sciencesmedical biotechnologycells technologiesstem cellsnatural sciencesbiological sciencesgeneticsmutationnatural sciencesmathematicspure mathematicsmathematical analysisfunctional analysismedical and health sciencesclinical medicineoncologyleukemia Programa(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Tema(s) ERC-2016-STG - ERC Starting Grant Convocatoria de propuestas ERC-2016-STG Consulte otros proyectos de esta convocatoria Régimen de financiación ERC-STG - Starting Grant Institución de acogida WEIZMANN INSTITUTE OF SCIENCE Aportación neta de la UEn € 1 750 000,00 Dirección HERZL STREET 234 7610001 Rehovot Israel Ver en el mapa Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 1 750 000,00 Beneficiarios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo WEIZMANN INSTITUTE OF SCIENCE Israel Aportación neta de la UEn € 1 750 000,00 Dirección HERZL STREET 234 7610001 Rehovot Ver en el mapa Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 1 750 000,00